| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Fructo-oligosaccharide DP7/GF6 targets the gut microbiome as a prebiotic. As a non-digestible carbohydrate, it passes through the upper gastrointestinal tract and is fermented by gut microbiota. This fermentation produces short-chain fatty acids that benefit gut health. The compound promotes the growth of beneficial gut bacteria. Fructooligosaccharides have been extensively studied for their prebiotic properties.
|
|---|---|
| ln Vitro |
In vitro, Fructo-oligosaccharide DP7/GF6 is a fructooligosaccharide used in prebiotic research. It is a non-digestible carbohydrate consisting of six fructose units linked to one terminal glucose. The compound is part of the fructan family. Its prebiotic potential is assessed in fermentation studies using gut microbiota cultures. FOS have been extensively studied for their prebiotic properties.
|
| ln Vivo |
In vivo, Fructo-oligosaccharide DP7/GF6 is a non-digestible carbohydrate that functions as a prebiotic. It promotes the growth of beneficial gut bacteria. As a fructooligosaccharide, it is fermented by gut microbiota to produce short-chain fatty acids that benefit gut health. The compound is widely used in prebiotic research. Further in vivo studies are ongoing to fully characterize its prebiotic effects.
|
| Enzyme Assay |
In vitro enzyme assays for Fructo-oligosaccharide DP7/GF6 involve measuring its fermentation by gut microbiota. Fecal samples are cultured in anaerobic conditions with the compound as a substrate. Short-chain fatty acid production is measured by GC. For prebiotic studies, the compound's effect on gut microbiota composition is assessed by 16S rRNA sequencing. Enzyme activities involved in fructooligosaccharide metabolism may be measured. Assays are performed in appropriate buffer systems with positive controls such as known prebiotics.
|
| Cell Assay |
In vitro cell-based assays for Fructo-oligosaccharide DP7/GF6 are conducted in gut epithelial cell lines and immune cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound or its fermentation products at varying concentrations. Cell viability is assessed by standard assays. Gut barrier function is assessed by measuring transepithelial electrical resistance. Immune modulation is assessed by measuring cytokine production. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Fructo-oligosaccharide DP7/GF6 in vivo studies are conducted in animal models of gut health and metabolic diseases. Animals are fed diets containing the compound. Gut microbiota composition is assessed by 16S rRNA sequencing. Short-chain fatty acid levels in feces and blood are measured. Gut barrier function and immune parameters are assessed. For metabolic studies, body weight, glucose tolerance, and lipid profiles are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Fructo-oligosaccharide DP7/GF6 (MW 1153.00 g/mol, C42H72O36) is a fructooligosaccharide with DP=7. It is soluble in DMSO at 100 mg/mL. It is stable under recommended storage conditions. Fructo-oligosaccharide DP7/GF6 is a prebiotic used in gut health research. Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Fructo-oligosaccharide DP7/GF6 is generally well-tolerated as a dietary oligosaccharide. The compound is a naturally occurring fructooligosaccharide. Its prebiotic effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Fructo-oligosaccharide DP7/GF6 is a fructooligosaccharide with DP=7 consisting of 6 fructose units and 1 glucose unit. It is a non-digestible carbohydrate and part of the fructan family that serves as a prebiotic. The compound promotes beneficial gut bacteria growth and is used in prebiotic research. Its molecular formula is C42H72O36 with a molecular weight of 1153.00 g/mol. All applications are limited to non-human research use.
|
| Molecular Formula |
C42H72O36
|
|---|---|
| Molecular Weight |
1152.9995
|
| Exact Mass |
1152.38
|
| CAS # |
62512-20-3
|
| PubChem CID |
50938613
|
| Appearance |
White to off-white solid powder
|
| Density |
1.89 g/cm3
|
| Boiling Point |
1475.2±65.0℃ at 760 mmHg
|
| LogP |
-12.9
|
| Hydrogen Bond Donor Count |
23
|
| Hydrogen Bond Acceptor Count |
36
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
78
|
| Complexity |
1920
|
| Defined Atom Stereocenter Count |
29
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO)O)O)O)O
|
| InChi Key |
RUCFLBDDUFAPAQ-LYUODHIZSA-N
|
| InChi Code |
InChI=1S/C42H72O36/c43-1-14-21(51)28(58)29(59)36(71-14)78-42(35(65)27(57)20(7-49)77-42)13-70-41(34(64)26(56)19(6-48)76-41)12-69-40(33(63)25(55)18(5-47)75-40)11-68-39(32(62)24(54)17(4-46)74-39)10-67-38(31(61)23(53)16(3-45)73-38)9-66-37(8-50)30(60)22(52)15(2-44)72-37/h14-36,43-65H,1-13H2/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28+,29-,30+,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-,41-,42+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8673 mL | 4.3365 mL | 8.6730 mL | |
| 5 mM | 0.1735 mL | 0.8673 mL | 1.7346 mL | |
| 10 mM | 0.0867 mL | 0.4337 mL | 0.8673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
